Back to search

Article

NEF2L2 rs35652124C>T Polymorphism Predicts Grade 4 Neutropenia in Esophageal Cancer Patients Treated with Docetaxel, Cisplatin, and Fluorouracil Chemotherapy: Results from Exploratory and Validation Cohorts

2025-10-23

Abstract excerpt

<title>Abstract</title> <p> Background Chemotherapy-induced neutropenia is a serious adverse event. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) is an effective neoadjuvant therapy for esophageal cancer, but it is associated with a high incidence of Grade 4 neutropenia. In previous study, we identified associations between genetic polymorphisms and severe neutropenia. The aim of t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
892b6761-21d7-53f1-ad8a-c7fbefe2244b
DOI
10.21203/rs.3.rs-7807601/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
NEF2L2 rs35652124C&gt;T Polymorphism Predicts Grade 4 Neutropenia in Esophageal Cancer Patients Treated with Docetaxel, Cisplatin, and Fluorouracil Chemotherapy: Results from Exploratory and Validation CohortsDOI 10.21203/rs.3.rs-7807601/v1
NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.Semantic proximity
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.Semantic proximity
Relevance of Pharmacogenetic Polymorphisms With Response to Docetaxel, Cisplatin, and 5-Fluorouracil Chemotherapy in Esophageal Cancer.Semantic proximity
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Semantic proximity
Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.Semantic proximity
ABCG2 genetic variant as a predictor of severe neutropenia in Japanese patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with palbociclib: an exploratory real-world studySemantic proximity
ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity
Development of a machine-learning model for therapeutic efficacy prediction of preoperative treatment for esophageal cancer using single nucleotide variants of autophagy-related genesSemantic proximity
ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity
Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer.Semantic proximity
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.Semantic proximity
MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.Semantic proximity
Select a neighboring publication to make it the new centre.